Suven Life Sciences has been granted a product patent by the US for the treatment of disorders associated with neuro-degenerative diseases.
In a BSE filing today, Suven Life said it has been granted “one product patent from the US corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.’’
The patents are valid till 2034, the company added.
Suven Life CEO Venkat Jasti said: “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”
With these new patents, Suven has 25 granted patents from the US.
“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.
Suven Life Sciences stock was trading 1.25 per cent up at Rs 178.75 on the BSE.